Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injury

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 3, 2012, Pages

  Li, Shenyang ^a   Nagothu, Kiran ^a   Ranganathan, Gouri ^b   Ali, Syed M ^a   Shank, Brian ^a   Gokden, Neriman ^a   Ayyadevara, Srinivas ^b   Megyesi, Judit ^a   Olivecrona, Gunilla ^e   Chugh, Sumant S ^d   Kersten, Sander ^c   Portilla, Didier ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UMEÅ UNIVERSITY   (Sweden)

Author keywords

Angiopoietin like protein 4; Lipase maturation factor 1; Peroxisome proliferator activated receptor

Indexed keywords

CISPLATIN; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REGULATOR PROTEIN; TRIACYLGLYCEROL;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; EPIDIDYMIS; KIDNEY PROXIMAL TUBULE; LIPOTOXICITY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE;

EID: 84864779617     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00111.2012     Document Type: Article

References (56)

1. Abdel-Gayoum AA, El-Jenjan KB, Ghwarsha KA. Hyperlipidemia in cisplatin-induced nephrotic rats. Hum Exp Toxicol 18: 454-459, 1999.
2. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11: 327-332, 2000.
3. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Sem Nephrol 23: 460-464, 2003.
4. Axelsson J, Astrom G, Sjolin E, Qureshi AR, Lorente-cebrian S, Stenvinkel P, Ryden M. Uraemic sera stimulate lipolysis in human adipocytes: role of perilipin. Nephrol Dial Transplant 26: 2485-2491, 2011.
5. Basi S, Pupim LB, Simmons EM, Sezer T, Shyr Y, Freedman S, Chertow GM, Mehta RL, Paganini E, Himmelfarb J, Ikizler TA. Insulin resistance in critically ill patients with acute renal failure. Am J Physiol Renal Physiol 289: F259-F264, 2005.
6. Beigneux AP, Davies BS, Gin P, Weinstein MM, Farber E, Qiao X, Peale P, Bunting S, Walzem RL, Wong JS. Glycosylphosphatidylinosi-tol-anchored high density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 5: 279-291, 2007.
7. Calandra S, Priore Oliva C, Tarugi P, Bertolini S. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol 17: 122-127, 2006.
8. Catapano AL. Apolipoprotein C-II and lipoprotein lipase activity. Ric Clin Lab 12: 35-40, 1982.
9. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 7: 3-18, 2007.
10. Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61: 223-242, 2009.
11. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstadt H, Lanvers-Kamisnky C, Zenhoff-dinnesen A, Scinkel AH, Koepsell H, Jurgens H, Schlatter E. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is target for protective interventions. Am J Pathol 176: 1169-1180, 2010.
12. Clement LC, Avila-Casado C, Mane C, Soria E, Bakker WW, Kersten S, Chugh SS. Podocyte-secreted angiopoietin-like 4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nature Med 17: 117-122, 2011.
13. Davies BS, Beigneux AP, Barnes RH, Tu Y, Gin P, Weinstein MM, Nobumori C, Nyren R, Goldberg G, Olivecrona G. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab 12: 42-52, 2010.
14. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320: 1060-1068, 1989.
15. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316: 129-139, 2010.
16. Géloën A, Trayhurn P. Regulation of the level of uncoupling protein in brown adipose tissue by insulin require the mediation of the sympathetic nervous system. FEBS Lett 267: 265-267, 1990.
17. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and A1. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 78: 1287-1295, 1986.
18. Goldberg IJ, Merkel M. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci 6: D388-D405, 2001.
19. Horkko S, Huttunen K, Korkonen T, Kesaniemi YA. Decreased clearance of low-density lipoprotein in patients with chronic renal failure. Kidney Int 45: 561-570, 1994.
20. Kersten S, Mandard S, Tang NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B, Wahli W. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 275: 28488-28493, 2000.
21. Köster A, Chao YB, Mosior M, Ford A, Gonzalez-DeWhitt PA, Hale JE, Li D, Qiu Y, Fraser CC, Yang DD, Heuer JG, Jaskunas SR, Eacho P. Transgenic angipoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 146: 4943-4950, 2005.
22. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61: 903-909, 2008.
23. Laurencikiene J, van Harmelen V, Arvidsson Nordstrom E, Dicker A, Blomqvist L, Naslund E, Langin D, Arner P, Ryden M. NF-kB is important for TNF-a-induced lipolysis in human adipocytes. J Lipid Res 48: 1069-1077, 2007.
24. Leverve XM, Cano NJ. Nutritional management in acute illness and acute kidney insufficiency. Contrib Nephrol 156: 112-118, 2007.
25. Li C. Genetics and regulation of angiopoietin-like proteins 3 and 4. Curr Opin Lipidol 17: 152-156, 2006.
26. Li S, Basnakian A, Bhatt R, Megyesi J, Gokden N, Shah SV, Portilla D. PPAR-a ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Am J Physiol Renal Physiol 287: F990-F998, 2004.
27. Li S, Gokden N, Okusa MD, Bhatt R, Portilla D. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 289: F469-F480, 2005.
28. Li S, Nagothu KK, Desai V, Lee T, Branham W, Moland C, Megyesi JK, Crew MD, Portilla D. Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-alpha in mice confers protection during acute kidney injury. Kidney Int 76: 1049-1062, 2009.
29. Li S, Wu P, Yarlagadda P, Vadjunec NM, Proia AD, Harris RA, Portilla D. PPAR a ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 286: F572-F580, 2004.
30. Mattijssen F, Kersten S. Regulation of triglyceride metabolism by angiopoietin-like proteins. Biochim Biophys Acta 1821: 782-789, 2012.
31. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl) 80: 753-769, 2002.
32. Nilsson-Ehle P, Schotz MC. A stable radioactive substate emulsion for assay of lipoprotein lipase. J Lipid Res 17: 536-541, 1976.
33. Oh JH, Baum DD, Pham S, Cox M, Nguyen ST, Ensor J, Chen I. Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol 24: 175-181, 2007.
34. Olafsen T, Yopung SG, Davies BS, Beigneux AP, Kenanova VE, Voss C, Young G, Wong KP, Tu Y. Unexpected expression pattern for glycosylphosphatidylinositol-anchored HDL-binding protein GPIHBP1 in mouse tissues revealed by positron emission tomography scanning. J Biol Chem 285: 39239-39248, 2010.
35. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotec-tive strategies. Kidney Int 73: 994-1007, 2008.
36. Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Se-min Nephrol 30: 570-581, 2010.
37. Peterfy M, Ben-Zeev Mao HZ, Weisglass-Volkov D, Aouizerat BE, Pullinger CR, Frost PH, Kane JP, Malloy MJ, Reue K, Pajukanta P, Doolittle MH. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nat Genet 39: 1483-1487, 2007.
38. Peterfy M. Lipase maturation factor 1: a lipase chaperone involved in lipid metabolism. Biochim Biophys Acta 1821: 790-794, 2012.
39. Portilla D, Dai G, McClure T, Bates L, Kurten R, Megyesi J, Price P, Li S. Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int 62: 1208-1218, 2002.
40. Portilla D, Li S, Nagothu KK, Megyesi J, Kaissling B, Schnackenberg L, Safirstein RL, Beger RD. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 69: 2194-2204, 2006.
41. Portilla D. Energy metabolism and cytotoxicity. Semin Nephrol 23: 432-438, 2003.
42. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
43. Ramesh G, Reeves WB. TNF-a mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110: 835-842, 2002.
44. Ranganathan G, Li C, Kern PA. The translational regulation of lipoprotein lipase in diabetic rats involves the 3'-untranslated region of lipoprotein lipase mRNA. J Biol Chem 275: 40986-40991, 2000.
45. Ranganathan S, Kern PA. Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes. J Biol Chem 273: 26117-26122, 1998.
46. Ruge T, Neuger L, Sukonina V, Wu G, Barath S, Gupta J, Frankel B, Christophersen B, Nordstoga K, Olivecrona T, Olivecrona G. Lipoprotein lipase in the kidney: activity varies widely among animal species. Am J Physiol Renal Physiol 287: F1131-F1139, 2004.
47. Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci USA 103: 17450-17455, 2006.
48. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60: 329-339, 2001.
49. Unger RH. Lipotoxic diseases. Annu Rev Med 53: 319-336, 2002.
50. Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 50: 1928-1935, 1996.
51. Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 6: 287-296, 2010.
52. Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism down-regulates lipoprotein lipase expression in chronic renal failure. Am J Physiol Renal Physiol 273: F925-F930, 1997.
53. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290: F262-F272, 2006.
54. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 297: E271-E288, 2009.
55. Weinberg JM. Lipotoxicity. Kidney Int 70: 1560-1566, 2006.
56. Zhang HH, Halbleib M, Ahmad F, Manganiello VC, Greenberg AS. Tumor necrosis factor-a stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51: 2929-2935, 2002.